吲哚布芬联合氯吡格雷治疗急性脑梗死的效果评价

目的 探讨吲哚布芬联合氯吡格雷治疗急性脑梗死的临床效果及药物安全性。方法 采用随机、对照的临床研究方法，选取温州市中心医院2021年6月至2022年12月的72例急性脑梗死患者为研究对象，分为对照组和试验组。试验组给予吲哚布芬片200mg，每日2次，联合氯吡格雷75mg，每日1次。对照组给予氯吡格雷75mg，每日1次。两组均采取神经内科常规内科治疗，给予醒脑静针20mg，每日1次静脉滴注；丁苯酞针100ml，每日2次静脉滴注；改善脑循环药物及其他降脂稳定斑块等药物对症支持治疗，并控制高血压、高血糖等基础疾病。治疗前后3周评估脑梗死相关量表指标。结果 治疗3周后，试验组与对照组的脑卒中量表评分较治疗前更低；试验组的治疗效果总有效率高于对照组，差异有统计学意义（P<0.05）。试验组与治疗前相比其生活质量评分有明显升高（P<0.001），对照组与治疗前相比其生活质量评分有升高（P<0.05）；试验组与对照组相比，其生活质量评分更高，差异有统计学意义（P<0.05）。两组胃痛、反酸发生率低，且两组比较差异均无统计学意义（P>0.05），两组均未发生消化道出血及颅内出血。结论 吲哚布芬联合氯吡格雷能提高急性脑梗死患者的治疗效果和生活质量评分，并且比单用氯吡格雷治疗效果更明显。与使用氯吡格雷单药治疗相比，吲哚布芬联合氯吡格雷治疗方案未明显增加患者不良反应的发生率。

Clinical effect of indobufen combined with clopidogrel on acute cerebral infarction

Objective To explore the clinical effect of indobufen combined with clopidogrel on acute cerebral infarction and analyze the drug safety. Methods Using a randomized and controlled clinical study method, 72 patients with acute cerebral infarction selected in Wenzhou Central Hospital from June 2021 to December 2022 were included in the study. They were randomly divided into control group and experimental group. The experimental group was given indobufen tablets 200mg (twice daily), and clopidogrel 75mg every day. The control group was treated with clopidogr el 75mg every day. The two groups were treated with conventional internal medicine in the department of neurology. They were given Xingnaojing Injection 20mg every day, and Butylphthalide Injection 100ml (twice daily). And they were given symptomatic support treatment with drugs to improve cerebral circulation and drugs to reduce blood fat and stabilize plaque. In addition, we control patients'' basic diseases such as hypertension and hyperglycemia. The indexes of cerebral infarction related scale were evaluated before treatment and after 3 weeks. Results After 3 weeks of treatment, the scores of stroke scale in the experimental group and the control group were lower than those before treatment. The total effective rate in the experimental group was higher than that in the control group, the difference was statistically significant (P<0.05). The score of Quality of Life in the experimental group was significantly higher than that before treatment (P<0.001). The score of Quality of Life in the control group was higher than that before treatment (P<0.05). Compared with the control group, the Quality of Life score of the experimental group was higher, with statistical significance (P<0.05). The incidence of stomachache and acid reflux in the two groups was low, and there was no statistically significant difference between the two groups (P>0.05). No gastrointestinal bleeding and intracranial hemorrhage occurred in the two groups. Conclusion Indobufen combined with clopidogrels can improve the treatment effect and Quality of Life score of patients with acute cerebral infarction, and is more obvious than clopidogrel alone. In addition, compared with clopidogrel monotherapy, indobufen combined with clopidogrel did not significantly increase the incidence of adverse reactions in patients.